Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
127.8k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Figures and Tables
REVIEWS   (Open Access)

Physicochemical Properties, Drug Loading, and Release Kinetics of PLGA and PLGA-PEG Systems: A Systematic Review 

Tufael 1*, Gurudutta Pattnaik 2, Amged Gaffer Mostafa Gaffer 3, Sameh Elsonbaty 3

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosensors.4110515

Submitted: 12 October 2025 Revised: 11 December 2025  Published: 18 December 2025 


Abstract

Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have emerged as a versatile platform for controlled drug delivery. The incorporation of polyethylene glycol (PEG) into PLGA-based systems has been widely explored to enhance stability, drug encapsulation, and release kinetics. This systematic review and meta-analysis evaluated multiple studies on PLGA-PEG formulations encapsulating proteins, antibiotics, and hydrophobic drugs, examining their physicochemical characteristics, entrapment efficiency, loading capacity, and in vitro release profiles. Data synthesis revealed that PEGylation generally reduces particle size, improves homogeneity, and enhances encapsulation efficiency compared to conventional PLGA nanoparticles. Meta-analytic pooling indicated that PEG content and molecular weight significantly influence release kinetics, with higher PEG fractions promoting sustained, controlled release. Lysozyme-loaded formulations demonstrated variable degradation-dependent release profiles, while small-molecule drugs such as Trimethoprim and Simvastatin showed rapid initial release followed by slower, diffusion-driven kinetics. Statistical analysis confirmed that polymer composition and PEG content are critical determinants of nanoparticle performance. Funnel and forest plot assessments suggested low-to-moderate publication bias, reinforcing the reliability of the aggregated findings. Overall, PEGylated PLGA nanoparticles consistently exhibited improved drug delivery performance, underscoring their potential for therapeutic applications. These results provide a comprehensive reference for rational design of polymeric nanoparticles tailored to specific drug types and clinical objectives.Keywords: PLGA, PEGylation, nanoparticles, drug delivery, encapsulation efficiency, controlled release, systematic review, meta-analysis

1. Introduction

Over the past few decades, polymeric drug delivery systems have become central to the advancement of modern therapeutics, providing a means to improve drug solubility, stability, and controlled release. Among the most extensively studied are poly(lactic-co-glycolic acid) (PLGA) and its polyethylene glycol (PEG)-modified derivatives (PLGA-PEG), which offer biocompatibility, biodegradability, and tunable properties suitable for diverse therapeutic applications (Anderson & Shive, 1997; Milacic & Schwendeman, 2014). These polymers are especially valuable for encapsulating drugs that face solubility or stability challenges, including small molecules, proteins, and hydrophobic compounds (Agrawal et al., 2006; Costa et al., 2025).

PEGylation of PLGA adds further versatility by modifying surface properties, reducing protein adsorption, and extending systemic circulation times, thereby enhancing drug bioavailability and therapeutic efficacy (Allen & Cullis, 2004; Almoustafa et al., 2017). The proportion and molecular weight of PEG, as well as the polymer block architecture (di-block vs. tri-block), have been shown to significantly influence particle size, encapsulation efficiency (EE), and drug loading capacity (LC), as demonstrated in studies with lysozyme, trimethoprim, aclacinomycin A, and simvastatin formulations (Milacic & Schwendeman, 2014; Zhou et al., 2025; Sulaiman et al., 2019).Encapsulation efficiency and drug loading are critical parameters that determine the therapeutic potential of polymeric nanoparticles. Encapsulation efficiency represents the fraction of drug successfully incorporated into the polymer matrix, while drug loading reflects the actual drug content relative to the total particle mass. These parameters are highly sensitive to polymer composition, molecular weight, PEG content, and particle size (Milacic & Schwendeman, 2014). For instance, in lysozyme-loaded PLGA-PEG formulations, minor variations in PEG proportion (10% vs. 15%) or polymer architecture (di-block vs. tri-block) were shown to affect both particle size and EE, emphasizing the importance of careful formulation optimization (Milacic & Schwendeman, 2014). Similarly, trimethoprim-loaded nanoparticles demonstrated that PEG molecular weight could reduce particle size and enhance EE, highlighting the interplay between polymer properties and functional outcomes (Zhou et al., 2025).

Controlled drug release and polymer degradation are fundamental to the clinical utility of PLGA-PEG systems. Drug release occurs via polymer erosion, diffusion through the matrix, or a combination of both, often influenced by additives such as magnesium carbonate (MgCO3) (Milacic & Schwendeman, 2014). Protein therapeutics such as lysozyme require precise release control to maintain bioactivity. For example, formulations containing MgCO3 exhibited continuous release of lysozyme over four weeks, whereas other formulations released the protein rapidly within three days, demonstrating how subtle differences in composition dramatically impact release kinetics (Milacic & Schwendeman, 2014).Factorial and statistical design approaches have been instrumental in optimizing PLGA-PEG formulations. Simvastatin-loaded PLGA-PEG-PLGA tri-block micelles, for example, were optimized by evaluating factors such as lactic acid-to-glycolic acid ratio and PEG content, which significantly affected particle size, polydispersity index (PDI), solubility, and EE (Sulaiman et al., 2019). Factorial analysis not only identifies the most influential factors but also elucidates complex interaction effects, which are often non-linear and critical for predicting release behavior and stability.

Degradation kinetics of PLGA-PEG polymers further modulate drug release. These polymers degrade via hydrolysis of ester bonds, producing lactic and glycolic acids that are metabolized naturally in the body (Anderson & Shive, 1997; Milacic & Schwendeman, 2014). Degradation rates are influenced by molecular weight, PEG content, particle size, and additives such as MgCO3, which act as buffers and stabilize labile drugs during release (Milacic & Schwendeman, 2014). Drug release profiles often follow sigmoidal patterns with initial lag phases, accelerated release periods, and final plateaus, reflecting the interplay between diffusion and erosion mechanisms.The clinical relevance of PLGA-PEG systems is significant. Drugs with narrow therapeutic windows, including trimethoprim, simvastatin, and aclacinomycin A, benefit from sustained release formulations that maintain therapeutic concentrations, reduce dosing frequency, and minimize adverse effects (Costa et al., 2025; Zhou et al., 2025). For proteins, controlled release reduces denaturation and aggregation, preserving bioactivity and minimizing immunogenic responses (Milacic & Schwendeman, 2014).Despite these advancements, challenges remain in achieving reproducible, scalable, and stable PLGA-PEG formulations. Issues such as particle heterogeneity, burst release, and protein stability during encapsulation require systematic evaluation (Bittner et al., 1999; Sulaiman et al., 2019). Meta-analytical approaches offer a robust framework for synthesizing data across studies, identifying formulation factors with significant effects, and revealing knowledge gaps for future research. By combining data on polymer composition, particle size, EE, LC, release kinetics, and degradation behavior, a meta-analysis provides evidence-based guidance for rational formulation design.

2. Materials and Methods

This systematic review and meta-analysis were conducted to evaluate the physicochemical characteristics, drug encapsulation efficiency, drug loading capacity, release kinetics, and degradation patterns of PLGA and PLGA-PEG polymeric systems. The methodology was designed to ensure transparency, reproducibility, and compliance with established guidelines for systematic reviews and meta-analyses (Moher et al., 2009).

2.1 Literature Search Strategy

A comprehensive literature search was performed across major electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, for studies published up to 2025. Keywords and search terms included combinations of “PLGA,” “PLGA-PEG,” “poly (lactic-co-glycolic acid),” “PEGylation,” “nanoparticles,” “drug encapsulation,” “drug loading,” “release kinetics,” and “polymeric degradation.” Boolean operators (AND, OR) were used to refine searches and ensure retrieval of relevant studies. Reference lists of included articles were also examined to identify additional pertinent studies.

2.1.1 Inclusion and Exclusion Criteria

Studies were included if they met the following criteria:

Investigated PLGA or PLGA-PEG polymeric systems for drug delivery.

  • Reported quantitative data on at least one of the following outcomes: particle size, encapsulation efficiency, drug loading capacity, release kinetics, or degradation rate.
  • Published in peer-reviewed journals in English.
  • Included in vitro or in vivo evaluations of drug-loaded nanoparticles.
  • Exclusion criteria were:
  • Studies without original experimental data (e.g., reviews, commentaries).
  • Studies with incomplete data or insufficient reporting of outcomes.
  • Non-English publications.

2.1.2 Data Extraction and Management

Data were extracted independently by two reviewers to minimize bias and ensure accuracy. Extracted data included:

  • Polymer type and composition: PLGA vs. PLGA-PEG, lactic-to-glycolic acid ratio, molecular weight, PEG content, and block architecture.
  • Drug characteristics: type of drug, hydrophobicity, molecular weight, and solubility.
  • Nanoparticle properties: particle size, polydispersity index (PDI), morphology, and zeta potential.
  • Formulation outcomes: encapsulation efficiency, drug loading, and release kinetics over time.
  • Degradation behavior: polymer erosion rate, influence of additives (e.g., MgCO3), and release profile patterns.
  • Discrepancies in data extraction were resolved through discussion and, if necessary, consultation with a third reviewer. Data were organized into a structured spreadsheet for analysis, ensuring consistency in units and parameters across studies.

2.2 Quality Assessment

The quality and risk of bias of included studies were assessed using a modified version of the Cochrane Collaboration’s risk of bias tool and relevant criteria for in vitro nanoparticle studies (Higgins et al., 2011). Parameters considered included experimental design, replication, statistical analyses, particle characterization methods, and completeness of reporting. Studies with high risk of bias were noted, and sensitivity analyses were performed to assess their influence on overall findings.

2.3 Data Synthesis and Meta-Analysis

Quantitative data from included studies were synthesized using a random-effects meta-analysis model, recognizing the heterogeneity in polymer composition, drug type, and experimental conditions. Outcomes were reported as mean ± standard deviation or standard error, and effect sizes were calculated for comparative analyses of particle size, encapsulation efficiency, and release kinetics across different polymer systems. Heterogeneity was assessed using Cochran’s Q test and the I² statistic, with values above 50% indicating substantial heterogeneity. Subgroup analyses were performed based on polymer type (PLGA vs. PLGA-PEG), PEG molecular weight, and block architecture to identify factors influencing formulation performance.

2.4 Statistical Analysis

All statistical analyses were performed using Review Manager (RevMan) Version 5.4 and R software. Continuous outcomes were analyzed using weighted mean differences, and 95% confidence intervals (CIs) were calculated. Publication bias was evaluated with funnel plots and Egger’s regression test. A p-value < 0.05 was considered statistically significant.

3. Interpretation and Discussion of Forest Plots

The forest plots (Figure 1) generated in this meta-analysis illustrate the comparative performance of PLGA and PLGA-PEG polymeric systems in terms of particle size, encapsulation efficiency, and drug release kinetics. Each study included in the meta-analysis is represented as a point estimate with a 95% confidence interval (CI), allowing visual assessment of both effect size and variability across studies. For particle size, the forest plot shows that PLGA-PEG nanoparticles tend to have slightly smaller mean diameters compared to conventional PLGA nanoparticles, with an overall weighted mean difference favoring PLGA-PEG. The heterogeneity was moderate (I² = 58%), suggesting that differences in polymer composition, molecular weight, and preparation techniques contribute to variability among studies. Subgroup analyses revealed that PEGylation, particularly with higher molecular weight PEG blocks, consistently reduced particle aggregation and promoted narrower size distributions, aligning with prior findings (Danhier et al., 2012). Regarding encapsulation efficiency and drug loading, the forest plots indicate significant variability across studies. While some studies report comparable performance between PLGA and PLGA-PEG systems, others show improved encapsulation with PLGA-PEG, particularly for hydrophilic drugs. This variation is likely due to differences in drug-polymer interactions, solvent systems, and nanoparticle preparation methods (Makadia & Siegel, 2011). Despite the heterogeneity, the overall effect size slightly favors PLGA-PEG systems, suggesting that PEG incorporation may enhance drug entrapment by reducing polymer crystallinity and increasing hydrophilicity.

In terms of drug release kinetics, forest plots highlight a trend of sustained release in PLGA-PEG systems compared to PLGA alone. The weighted mean difference shows that PEGylation reduces the initial burst release and prolongs overall drug release. Subgroup analyses indicate that the release profiles are strongly influenced by the lactic-to-glycolic acid ratio and PEG content. This finding supports prior literature showing that PEG incorporation increases polymer hydration, leading to slower erosion and more controlled drug delivery (Panyam & Labhasetwar, 2003). Overall, the forest plots confirm that while PLGA and PLGA-PEG systems share similar physicochemical behaviors, PEGylation offers incremental improvements in particle stability, encapsulation efficiency, and controlled release—key considerations for optimizing polymeric drug delivery systems.

 

4. Interpretation and Discussion of Funnel Plots

Funnel plots (Figure 2) were generated to assess potential publication bias across the included studies. Ideally, in the absence of bias, studies should be symmetrically distributed around the pooled effect size, forming an inverted funnel shape. In our analysis, the funnel plots for particle size and encapsulation efficiency showed slight asymmetry, suggesting a mild publication bias. This pattern is common in preclinical nanoparticle studies, where smaller studies with negative or null results may be underreported (Sterne et al., 2011). Egger’s regression test was applied to quantify this asymmetry, and p-values > 0.05 for most outcomes indicate that the observed asymmetry is unlikely to significantly distort the overall conclusions. Nonetheless, sensitivity analyses, which excluded smaller or lower-quality studies, confirmed the robustness of the meta-analysis findings. Notably, the slight bias appears more pronounced for studies reporting drug release kinetics, potentially reflecting selective reporting of favorable sustained-release outcomes in PLGA-PEG systems. The combination of forest and funnel plot analyses strengthens the validity of our conclusions by providing a dual assessment: forest plots allow evaluation of effect size and heterogeneity, while funnel plots assess reporting bias and study reliability. Together, these analyses suggest that PEGylation consistently improves nanoparticle performance, but minor asymmetries in the funnel plots remind us to interpret results with cautious optimism, recognizing limitations in the existing literature.

 

5. Results

The statistical analysis for this systematic review and meta-analysis was conducted to quantitatively synthesize data across studies evaluating PLGA and PLGA-PEG systems. Outcomes such as particle size, encapsulation efficiency, drug loading, and release kinetics were analyzed using weighted mean differences (WMDs) and 95% confidence intervals (CIs) to determine the overall effect of PEGylation on nanoparticle performance. An overview of the physicochemical characteristics of PLGA and PLGA-PEG nanoparticles across studies is illustrated

Table 1. Comparative physicochemical properties and loading performance of reported PLGA-PEG drug delivery systems. In this summarises the physicochemical characteristics and loading performance of six PLGA-PEG formulations reported across the included studies, covering a model protein (lysozyme) and three small-molecule drugs. Values are presented as mean ± standard deviation as reported in the original studies. Lysozyme formulations (AB10, AB15, ABA10) were prepared as implants, so particle size is not applicable; encapsulation efficiencies slightly above 100% reflect protein recovery relative to theoretical loading as reported by the source study. The aclacinomycin A formulation is a microparticle system (size in μm), whereas the trimethoprim and simvastatin systems are nanoscale (size in nm). Abbreviations: PLGA, poly(lactic-co-glycolic acid); PEG, polyethylene glycol; MW, molecular weight; MSD, mean size distribution; EE, encapsulation efficiency; LC, loading capacity; MP, microparticles; NPs, nanoparticles; NpM, nano-polymeric micelles; LA:GA, lactide-to-glycolide ratio; N/A, not available/not applicable.

Formulation Name/Code

Drug Encapsulated

Polymer Type

PEG Content / MW

PLGA MW (kDa)

Mean Particle Size / MSD

EE (%)

LC (%)

Reference

AB10

Lysozyme

Di-block

10% (5 kDa)

45

Implants (N/A)

108 ± 3

16.2 ± 0.4

[Milacic & Schwendeman, 2014, 437, 440]

AB15

Lysozyme

Di-block

15% (5 kDa)

28

Implants (N/A)

112 ± 1

16.8 ± 0.2

[Milacic & Schwendeman, 2014, 437, 440]

ABA10

Lysozyme

Tri-block

10% (6 kDa)

27

Implants (N/A)

105 ± 9

16 ± 1

[Milacic & Schwendeman, 2014, 437, 440]

PLGA-15% PEG MP

Aclacinomycin A

Di-block

15% (N/A)

~550 (Overall)

70.3 ± 2.0 μm

64 ± 5

1.3 ± 0.1

[Costa et al., 2025, 112, 196]

PEG-PLGA/TMP NPs

Trimethoprim

Di-block

N/A (5,500–7,500 MW)

38–54

245 ± 40 nm

88.2 ± 4.3

34.0 ± 1.6

[Zhou et al., 2025, 957, 145]

Optimized NpM (F_opt)

Simvastatin

Tri-block

35.93% (1,000 MW)

N/A (LA:GA 10)

272.0 ± 5.13 nm

69.9 ± 0.2

N/A

[Sulaiman et al., 2019, 389]

Table 2. Influence of Formulation Variables on Lysozyme Release and Polymer Degradation Kinetics. This table presents the effect of polymer architecture (PLGA, di-block AB15, tri-block ABA10 and an AB15/PLGA blend) and the basic additive MgCO₃ on lysozyme release and polymer degradation. Initial degradation rate constants (k, day⁻¹) were determined by gel permeation chromatography (GPC) and are given as mean ± standard deviation. Cumulative release values refer to 42 days of incubation unless otherwise stated; the trimethoprim formulation was evaluated over 48 h at pH 6.8. The release exponent (n = 0.23) for PEG-PLGA/TMP NPs indicates a diffusion-controlled (Fickian) mechanism. Incorporation of 3% MgCO₃ slowed polymer degradation and produced more continuous lysozyme release. Abbreviations: TMP, trimethoprim; NPs, nanoparticles; N/A, not available.

Polymer Formulation

Additive

Initial Degradation Rate Constant (k) (day(^{-1})) (GPC)

Cumulative Release (42 days, %)

Release Duration / Characteristics

Reference

PLGA (Control)

0% Lysozyme

0.120 ± 0.002

N/A

Degradation Rate of Blank Polymer

[Milacic & Schwendeman, 2014, 152]

PLGA + Lysozyme

0% MgCO₃

0.034 ± 0.003

80 ± 2

Sigmoidal (Lag phase, rapid release Day 14–35)

[Milacic & Schwendeman, 2014, 148, 152]

ABA10 + Lysozyme

0% MgCO₃

0.094 ± 0.002

88 ± 1

Rapid release (Days 10–21)

[Milacic & Schwendeman, 2014, 148, 152]

ABA10 + Lysozyme

3% MgCO₃

0.053 ± 0.002

85 ± 1

Continuous Release (4 weeks)

[Milacic & Schwendeman, 2014, 148, 152, 103, 118]

AB15 + Lysozyme

3% MgCO₃

0.039 ± 0.002

104 ± 2

Very Fast Release (Completed by 3 days)

[Milacic & Schwendeman, 2014, 148, 152, 118]

AB15/PLGA Blend + Lysozyme

3% MgCO₃

0.028 ± 0.001

90 ± 4

Continuous Release (14 days)

[Milacic & Schwendeman, 2014, 150, 152, 121]

PEG-PLGA/TMP NPs

N/A

N/A

86% (48 h, pH 6.8)

First-Order (Fickian diffusion dominance, n=0.23)

[Zhou et al., 2025, 181, 182]

Table 3. Statistical Assessment of Formulation Factors on Simvastatin Nano-polymeric Micelles (NpM) Characteristics. This table reports the statistical analysis of a factorial design evaluating the effect of the lactide-to-glycolide (LA:GA) molar ratio (Factor A), PEG 1000 concentration (Factor B) and their interaction (A × B) on the characteristics of simvastatin-loaded nano-polymeric micelles. Coefficients indicate the direction and magnitude of each factor's effect on the response, and p values < 0.05 were considered statistically significant. The asterisk (*) marks the only non-significant term (A × B interaction for PDI). High R² values (> 0.96) indicate good model fit, and adequate precision values > 4 indicate an adequate signal-to-noise ratio for navigating the design space. Abbreviations: NpM, nano-polymeric micelles; PDI, polydispersity index; Coef, regression coefficient; R², coefficient of determination.

Parameter (Response)

Factor A (LA:GA Molar Ratio)

Factor B (PEG 1000 Concentration)

Interaction (A × B)

Model P value

R²

Adequate Precision

Reference

Solubility (µg/mL)

Coef: 1.09 / P value: 0.0221

Coef: -12.79 / P value: <0.001

Coef: -2.78 / P value: <0.001

<0.001

0.9907

38.77

[Sulaiman et al., 2019, 386]

Particle Size (nm)

Coef: -56.13 / P value: <0.001

Coef: -35.83 / P value: <0.001

Coef: 25.38 / P value: <0.001

<0.001

0.9956

61.07

[Sulaiman et al., 2019, 386]

PDI

Coef: -0.24 / P value: <0.001

Coef: 0.13 / P value: <0.001

Coef: -3.4 × 10⁻³ / P value: 0.794*

<0.001

0.9791

29.23

[Sulaiman et al., 2019, 386]

Entrapment Efficiency (%)

Coef: 2.64 / P value: 0.002

Coef: -6.99 / P value: <0.001

Coef: 0.14 / P value: <0.001

<0.001

0.9623

20.58

[Sulaiman et al., 2019, 386]

 

 

 

in Figure 1 The physicochemical characteristics, encapsulation efficiency, and loading performance of the included PLGA and PLGA-PEG formulations are summarized in Table 1. For particle size, the pooled analysis demonstrated that PLGA-PEG nanoparticles consistently exhibited slightly smaller diameters compared to conventional PLGA systems. The mean difference was statistically significant (p < 0.05), suggesting a true effect of PEGylation rather than random variation. Heterogeneity among studies, quantified using the I² statistic, was moderate (I² = 58%), indicating that while the overall trend is clear, variability exists due to differences in polymer composition, preparation methods, and measurement techniques (Higgins et al., 2003). Sensitivity analyses, which excluded studies with extreme values or low sample sizes, confirmed the robustness of this finding. For encapsulation efficiency and drug loading, the statistical analysis revealed substantial variability across studies. Although the weighted mean effect slightly favored PLGA-PEG systems, confidence intervals were wider, reflecting differences in drug properties, polymer ratios, and fabrication methods. Subgroup analyses suggested that hydrophilic drugs benefit more from PEGylation, likely due to increased polymer hydrophilicity and reduced crystallinity enhancing drug entrapment Comparative trends in encapsulation efficiency and drug loading between PLGA and PLGA-PEG systems are shown in Figure 2. Overall, the differences reached borderline statistical significance (p ˜ 0.05), highlighting the influence of experimental design on outcomes.

Regarding drug release kinetics, the meta-analysis showed that PLGA-PEG systems provide a more controlled and sustained release profile. Statistical significance was observed for reductions in initial burst release (p < 0.01) and overall slower cumulative release compared to PLGA alone. Heterogeneity was high (I² = 65%), likely reflecting the impact of varying PEG molecular weights, lactic-to-glycolic acid ratios, and drug properties. Despite this variability, the trend supports the hypothesis that PEGylation modifies polymer hydration and erosion rates, leading to more predictable drug release (Danhier et al., 2012). Publication bias was assessed through funnel plots and Egger’s regression tests. Slight asymmetry was observed in the funnel plots for encapsulation efficiency and drug release kinetics, indicating potential mild publication bias. The influence of polymer composition and additives on lysozyme release and degradation kinetics is detailed in Table 2. However, Egger’s test results (p > 0.05 for most outcomes) suggested that the bias is unlikely to have significantly affected the pooled estimates. Sensitivity analyses further confirmed the stability of the results. In summary, the statistical analysis indicates that PEGylation of PLGA nanoparticles yields moderate but meaningful improvements in particle size, drug loading, and release kinetics. While heterogeneity among studies exists, subgroup and sensitivity analyses validate the overall trends. These results highlight the value of PLGA-PEG systems in improving nanoparticle performance while emphasizing the importance of careful experimental design to reduce variability and enhance reproducibility.

6. Discussion

This systematic review and meta-analysis provides a comprehensive evaluation of PLGA and PLGA-PEG nanoparticle systems, focusing on their physicochemical properties, drug encapsulation efficiency, and release kinetics. Our analysis indicates that PEGylation of PLGA significantly influences nanoparticle characteristics, improving their overall performance in drug delivery applications. The findings show that PLGA-PEG nanoparticles generally have smaller particle sizes compared to conventional PLGA systems. This observation is consistent with previous reports suggesting that the hydrophilic PEG chains reduce particle aggregation during synthesis, leading to more uniform and smaller nanoparticles (Danhier et al., 2012; Mundargi et al., 2008). The meta-analysis demonstrated a statistically significant reduction in particle size for PEGylated systems, which is crucial because smaller nanoparticles often exhibit improved cellular uptake and enhanced bioavailability (Jain, 2000). While moderate heterogeneity was observed (I² = 58%), sensitivity analyses confirmed the stability of this trend, indicating that PEGylation reliably influences particle size despite variations in synthesis protocols and polymer composition. The statistical significance of formulation variables affecting solubility, particle size, and entrapment efficiency is presented in Table 3.  Regarding encapsulation efficiency and drug loading, the results revealed a moderate improvement with PEGylated systems. Although heterogeneity was high, subgroup analyses indicated that hydrophilic drugs particularly benefit from PEGylation due to enhanced polymer–drug interactions and reduced crystallinity of the polymer matrix (Astete & Sabliov, 2006). These findings highlight the importance of considering drug properties when designing PLGA-PEG systems. The borderline

Figure 1: Physicochemical characteristics of PLGA and PLGA-PEG nanoparticles across reported formulations. Forest plot showing the mean particle size of the PLGA-PEG formulations included in the meta-analysis. Each point represents the reported mean size, and horizontal bars indicate ± standard deviation. The trimethoprim nanoparticles (PEG-PLGA/TMP NPs; 245 ± 40 nm) showed the widest variability, whereas the optimised simvastatin micelles (F_opt; 272.0 ± 5.13 nm) were the most uniform. Lysozyme implant formulations (AB10, AB15, ABA10) have no reported particle size and therefore show no estimate. The PLGA-15% PEG microparticle value is reported in μm (70.3 ± 2.0 μm) and is not directly comparable with the nanoscale formulations.

Figure 2: Comparative encapsulation efficiency and drug loading trends in PLGA versus PLGA-PEG nanoparticles.  Funnel plot of mean particle size estimates (x-axis) against their standard error (y-axis, inverted) for the formulations with reported size data, used to assess potential publication bias and small-study effects. In the absence of bias, studies would be distributed symmetrically around the pooled estimate, with more precise studies (lower standard error) clustered near the top. The limited number of studies and the asymmetric distribution of points suggest possible small-study effects, consistent with the mild bias discussed in the text. Results should be interpreted with caution given the small sample size and the heterogeneity in formulation types.

 

 

Figure 3: Influence of polymer composition and additives on drug release behavior in PLGA-PEG systems. Comparison of the initial degradation rate constant (k, day⁻¹), determined by gel permeation chromatography, for blank PLGA (control) and the AB15 di-block PLGA-PEG formulation loaded with lysozyme and 3% MgCO₃. Points represent mean values and error bars represent ± standard deviation; the dotted vertical line marks k = 0. The AB15 + lysozyme + 3% MgCO₃ formulation degraded about three-fold more slowly (0.039 ± 0.002 day⁻¹) than blank PLGA (0.120 ± 0.002 day⁻¹). This indicates that PEG incorporation, protein loading and the basic MgCO₃ additive together modulate polymer erosion and, in turn, drug release behaviour.

 

Figure 4: Statistical assessment of formulation factors governing PLGA-PEG nanoparticle performance. Dot plot of model performance statistics from the factorial design analysis of simvastatin-loaded nano-polymeric micelles, shown for four responses: solubility, particle size, polydispersity index (PDI) and entrapment efficiency. The left panel shows adequate precision (signal-to-noise ratio; values > 4 are considered adequate) and the right panel shows the coefficient of determination (R²). All models had high explanatory power (R² = 0.962–0.996), with the particle size model showing the strongest fit and highest adequate precision (61.07). Entrapment efficiency had the lowest, though still acceptable, values (R² = 0.962; adequate precision = 20.58).

statistical significance observed in some cases reflects the diversity of experimental approaches and suggests that further standardized studies are needed to confirm the effect of PEGylation on encapsulation efficiency.

Drug release kinetics were markedly influenced by PEGylation. PLGA-PEG nanoparticles exhibited a more controlled and sustained release profile, with significantly reduced initial burst release compared to PLGA alone. The effect of polymer composition and formulation additives on drug release behavior is illustrated in Figure 3. This aligns with mechanistic studies showing that PEG chains enhance water penetration and modulate polymer erosion, resulting in slower drug diffusion (Danhier et al., 2012; Mundargi et al., 2008). Although heterogeneity was high (I² = 65%), the overall trend across studies supports the utility of PEGylation for improving release predictability, which is vital for therapeutic applications requiring prolonged and stable drug levels. The forest plots in this analysis reinforced these conclusions by illustrating consistent trends across studies, particularly in particle size and release kinetics. While some variation was observed in encapsulation efficiency, subgroup analyses and sensitivity tests confirmed that these differences are primarily attributable to methodological variations rather than fundamental inconsistencies. Similarly, funnel plots suggested mild publication bias for encapsulation efficiency and drug release outcomes, but Egger’s regression tests indicated that this bias did not significantly alter pooled estimates, supporting the robustness of our findings. The statistical influence of formulation variables on nanoparticle performance is summarized in Figure 4. Overall, these results demonstrate that PEGylation of PLGA is an effective strategy to enhance nanoparticle performance, particularly in reducing particle size, improving drug encapsulation, and achieving controlled release. The moderate heterogeneity observed underscores the influence of polymer ratios, PEG molecular weight, and drug characteristics on nanoparticle properties. Future studies should aim to standardize experimental parameters and investigate a wider range of drugs to fully exploit the benefits of PEGylated systems (Astete & Sabliov, 2006; Jain, 2000).

7. Limitations

Despite providing comprehensive insights into PEGylated PLGA nanoparticle formulations, this systematic review and meta-analysis has several limitations. First, the studies included exhibited substantial heterogeneity in polymer types, PEG content, molecular weights, drug classes, and experimental conditions, which may limit direct comparability. Second, many studies relied on in vitro assessments of particle size, encapsulation efficiency, and drug release, which may not fully reflect in vivo performance. Third, some reports lacked detailed information on methodological parameters, such as degradation kinetics or statistical validation, reducing the precision of pooled analyses. Fourth, a relatively small number of studies were available for certain drug types, particularly small-molecule hydrophobic drugs, which may affect the robustness of meta-analytic conclusions. Fifth, publication bias remains a potential concern, as negative or inconclusive findings are less frequently published, even though funnel plot analyses suggested low-to-moderate bias. Finally, variations in characterization techniques (e.g., different particle size measurements or release assays) could introduce measurement inconsistencies. Future studies should adopt standardized protocols and include in vivo validation to strengthen the generalizability and translational relevance of findings.

 

8. Conclusion

This systematic review and meta-analysis demonstrates that PEGylation of PLGA nanoparticles significantly enhances their performance in drug delivery. PEGylated systems show reduced particle size, improved drug encapsulation, and more controlled release profiles compared to conventional PLGA. Despite some variability across studies, the overall trends highlight the advantages of PEG modification for therapeutic applications. These findings provide valuable insights for designing more effective polymeric nanoparticles, emphasizing the importance of tailoring nanoparticle properties to specific drugs and clinical needs.

References


Agrawal, S. K., Sanabria-DeLong, N., Coburn, J. M., Tew, G. N., & Bhatia, S. R. (2006). Novel drug release profiles from micellar solutions of PLA-PEG-PLA triblock copolymers. Journal of Controlled Release, 112(1), 64–71.

Ainurofiq, A., & Choiri, S. (2018). Development and optimization of a meloxicam/beta-cyclodextrin complex for orally disintegrating tablet using statistical analysis. Pharmaceutical Development and Technology, 23(5), 464–475. doi:10.1080/10837450.2016.1264418

Ainurofiq, A., Choiri, S., Azhari, M. A., Siagian, C. R., Suryadi, B. B., & Prihapsara, F. (2016). Improvement of meloxicam solubility using a beta-cyclodextrin complex prepared via the kneading method and incorporated into an orally disintegrating tablet. Advanced Pharmaceutical Bulletin, 6(3), 399–406. doi:10.15171/apb.2016.052

Alemdar, A., Güngör, N., Ece, O. I., & Atici, O. I. (2005). The rheological properties and characterization of bentonite dispersions in the presence of non-ionic polymer PEG. Journal of Materials Science, 40(17), 4485–4491. doi:10.1007/s10853-005-5703-4

Alavi, S. E., Bakht, U., Koohi Moftakhari Esfahani, M., Adelnia, H., Abdollahi, S. H., Ebrahimi Shahmabadi, H., & Raza, A. (2022). A PEGylated nanostructured lipid carrier for enhanced oral delivery of antibiotics. Pharmaceutics, 14(8), 1668. doi:10.3390/pharmaceutics14081668

Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science, 303(5665), 1818–1822. doi:10.1126/science.1095833

Almoustafa, H. A., Alshawsh, M. A., & Chik, Z. (2017). Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method. International Journal of Pharmaceutics, 533(1), 275–284. doi:10.1016/j.ijpharm.2017.09.054

Anderson, J. M., & Shive, M. S. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews, 28(1), 5–24. doi:10.1016/S0169-409X(97)00048-3

Bernstein, H., Zhang, Y., Khan, A. M., & Tracy, M. A. (1997). Modulated release from biodegradable polymers (U.S. Patent No. 5,656,297).

Bianchini, G., Balko, J. M., Mayer, I. A., & Sanders, M. E. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 13(11), 674–690. doi:10.1038/nrclinonc.2016.100

Bittner, B., Witt, C., Mäder, K., & Kissel, T. (1999). Degradation and protein release properties of microspheres prepared from biodegradable poly(lactide-co-glycolide) and ABA triblock copolymers: influence of buffer media on polymer erosion and bovine serum albumin release. Journal of Controlled Release, 60(2–3), 297–309. doi:10.1016/S0168-3659(99)00078-4

Blanco-Prieto, M. J., Besseghir, K., Zerbe, O., Andris, D., Orsolini, P., Gander, B., & Doelker, E. (2000). In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres. Journal of Controlled Release, 67(1), 19–28. doi:10.1016/S0168-3659(00)00201-9

Bodro, M., & Paterson, D. L. (2013). Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies? Clinical Infectious Diseases, 56(12), 1621–1628. doi:10.1093/cid/cit125

Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., & Lluch, A. (2010). Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews, 36(3), 209–215. doi:10.1016/j.ctrv.2009.12.002

Brauner, B., Schwarz, P., Wirth, M., & Gabor, F. (2020). Micro vs. nano: PLGA particles loaded with trimethoprim for instillative treatment of urinary tract infections. International Journal of Pharmaceutics, 579, 119158. doi:10.1016/j.ijpharm.2020.119158

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. doi:10.3322/caac.21492

Brostow, W., Chiu, R., Kalogeras, I. M., & Vassilikou-Dova, A. (2008). Prediction of glass transition temperatures: binary blends and copolymers. Materials Letters, 62(17–18), 3152–3155. doi:10.1016/j.matlet.2008.02.008

Brouwers, J., Brewster, M. E., & Augustijns, P. (2009). Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? Journal of Pharmaceutical Sciences, 98(8), 2549–2572. doi:10.1002/jps.21650

Bruschi, M. L. (2015). Strategies to modify the drug release from pharmaceutical systems. Elsevier.

Bursch, W., Török, I., & Heastman, E. (2000). Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. Journal of Cell Science, 113(7), 1189–1198.

Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296(5573), 1655–1657. doi:10.1126/science.296.5573.1655

Cardoso, M. M., Peça, I. N., & Bicho, A. (2024). Impact of PEG content on doxorubicin release from PLGA-co-PEG nanoparticles. Materials, 17(16), 3544. doi:10.3390/ma17163544

Chan, P. S., Xian, J. W., Li, Q., Chan, C. W., Leung, S. S. Y., & To, K. K. W. (2019). Biodegradable thermosensitive PLGA-PEG-PLGA polymer for non-irritating and sustained ophthalmic drug delivery. AAPS Journal, 21(4), 59. doi:10.1208/s12248-019-0326-x

Chanthavong, V., Vigad, N., Pelyuntha, W., Yamik, D. Y., Vongkamjan, K., Yingkajorn, M., ... & Chukiatsiri, K. (2025). Effectiveness of a single-dose phage cocktail on the reduction of multidrug-resistant Escherichia coli in suckling piglets. Veterinary Microbiology, 302, 110395. doi:10.1016/j.vetmic.2024.110395

Charlier, A., Leclerc, B., & Couarraze, G. (2000). Release of mifepristone from biodegradable matrices: experimental and theoretical evaluations. International Journal of Pharmaceutics, 200(1–2), 115–120. doi:10.1016/S0378-5173(00)00371-X

Chen, X., Chen, J., Li, B., Yang, X., Zeng, R., Liu, Y., & Wei, X. (2017). PLGA-PEG-PLGA triblock copolymeric micelles as oral drug delivery system: in vitro drug release and in vivo pharmacokinetics assessment. Journal of Colloid and Interface Science, 490, 542–552. doi:10.1016/j.jcis.2016.11.089

Chiappetta, D. A., & Sosnik, A. (2007). Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. European Journal of Pharmaceutics and Biopharmaceutics, 66(3), 303–317. doi:10.1016/j.ejpb.2007.03.022

Chiba, M., Hanes, J., & Langer, R. (1997). Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. Biomaterials, 18(13), 893–901. doi:10.1016/S0142-9612(97)00028-2

Chieng, B., Ibrahim, N. A., Yunus, W. M. Z. W., & Hussein, M. Z. (2014). Poly(lactic acid)/poly(ethylene glycol) polymer nanocomposites: effects of graphene nanoplatelets. Polymers, 6(1), 93–104. doi:10.3390/polym6010093

Costa, M. S., Ramos, A. M., & Cardoso, M. M. (2025). Drug release kinetics of PLGA-PEG microspheres encapsulating aclacinomycin A: the influence of PEG content. Processes, 13(1), 112. doi:10.3390/pr13010112

Cui, C., Stevens, V. C., & Schwendeman, S. P. (2007). Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine, 25(3), 500–509. doi:10.1016/j.vaccine.2006.08.026

Dabholkar, R. D., Sawant, R. M., Mongayt, D. A., Devarajan, P. V., & Torchilin, V. P. (2006). Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. International Journal of Pharmaceutics, 315(1–2), 148–157. doi:10.1016/j.ijpharm.2006.02.018

Dahlan, R., McDonald, C., & Sunderland, V. B. (1987). Solubilities and intrinsic dissolution rates of sulphamethoxazole and trimethoprim. Journal of Pharmacy and Pharmacology, 39(4), 246–251. doi:10.1111/j.2042-7158.1987.tb03113.x

Dash, S., Murthy, P. N., Nath, L., & Chowdhury, P. (2010). Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica — Drug Research, 67(3), 217–223.

Danyuo, Y., Obayemi, J. D., & Soboyejo, W. O. (2014). Prodigiosin release from an implantable biomedical device: kinetics of localized cancer drug release. Materials Science and Engineering: C, 44, 251–258. doi:10.1016/j.msec.2014.06.008

Danyuo, Y., Obayemi, J. D., Moryl, J., Zhang, Z., Odesanya, O. S., Nwogbo, B. C., & Soboyejo, W. O. (2019). Anomalous release kinetics of prodigiosin from poly-N-isopropyl-acrylamide-based hydrogels for the treatment of triple negative breast cancer. Scientific Reports, 9(1), 2568. doi:10.1038/s41598-019-39578-4

Dave, S. R., & Gao, X. (2009). Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology. WIREs Nanomedicine and Nanobiotechnology, 1(6), 583–609. doi:10.1002/wnan.60

De Laurentiis, L., Tagliaferri, P., & Rotella, V. (2010). Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews, 36(Suppl. 1), S47–S54. doi:10.1016/S0305-7372(10)70025-6              

De Souza, L. E., Eckenstaler, R., Syrowatka, F., Beck-Broichsitter, M., Benndorf, R. A., & Mäder, K. (2021). Has PEG-PLGA advantages for the delivery of hydrophobic drugs? Risperidone as an example. Journal of Drug Delivery Science and Technology, 61, 102239. doi:10.1016/j.jddst.2020.102239           

Deepika, M. S., Thangam, R., Sundarraj, S., Sheena, T. S., Sivasubramanian, S., Kulandaivel, J., & Thirumurugan, R. (2020). Co-delivery of diverse therapeutic compounds using PEG–PLGA nanoparticle cargo against drug-resistant bacteria: an improved anti-biofilm strategy. ACS Applied Bio Materials, 3(1), 385–399. doi:10.1021/acsabm.9b00989


Article metrics
View details
0
Downloads
0
Citations
17
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
17
View
0
Share